Medical News

RSS

Bariatric surgery patients report better quality of life

A study by Cleveland Clinic researchers shows bariatric surgery is a highly effective and durable treatment for type 2 diabetes in obese patients, enabling nearly all surgical patients to be free of insulin and many to be free of all diabetic medications three years after surgery.

31 Mar 2014

NxStage Medical receives American Red Cross Northeast Chapter's Workplace Hero Award

NxStage Medical Inc., a leading manufacturer of home dialysis products, today announced the Company has been awarded the 2014 Workplace Hero Award by the Northeast Chapter of the American Red Cross.

31 Mar 2014

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Prana Biotechnology has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results.

31 Mar 2014

Verde Media Group, Biotech Division complete acquisition of Butazyme

Verde Media Group Inc. and its Biotech Division announce they have completed the acquisition of the privately held biotechnology company Butazyme LLC.

31 Mar 2014

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

31 Mar 2014

BCBSA honors Empire BlueCross BlueShield with Brand Excellence Award

Empire BlueCross BlueShield announced today that it has received a Brand Excellence Award from the Blue Cross and Blue Shield Association. The annual awards honor Blue Cross and Blue Shield companies that excel in developing and enhancing the overall Blue Cross and Blue Shield Brand image.

31 Mar 2014

FitLife Brands' fourth quarter 2013 revenue increases 9% to $3.7 million

FitLife Brands, Inc., an international provider of innovative and proprietary nutritional supplements for health conscious consumers marketed under the brand names NDS Nutrition Products, PMD, SirenLabs and CoreActive today announced financial results for the fiscal year ended December 31, 2013.

31 Mar 2014

Enrollment commences for Daiichi Sankyo's ENSURE-AF multinational phase 3 study in NVAF patients

Daiichi Sankyo Company, Limited today announced that it has started enrolling patients into the ENSURE-AF multinational phase 3 study, which will evaluate the efficacy and safety of its investigational oral, once-daily direct factor Xa-inhibitor edoxaban compared to enoxaparin/warfarin for the prevention of stroke and other blood clot complications in patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion (low-energy shocks to trigger normal heart rhythm).

31 Mar 2014

New study shows anti-anxiety drugs and sleeping pills associated with increased risk of death

Anti-anxiety drugs and sleeping pills have been linked to an increased risk of death, according to new research from the University of Warwick.

31 Mar 2014

ICON agrees to acquire Aptiv Solutions for $143.5 million

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to certain closing conditions, to acquire Aptiv Solutions for a cash consideration of $143.5 million. Aptiv Solutions is owned by The Halifax Group, SV Life Sciences, Comvest Partners and Management.

31 Mar 2014

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).

31 Mar 2014

ZO Skin Health, Cellogique announce launch of ZO Medical products in Middle East

ZO Skin Health, Inc. and Cellogique Corporation are pleased to announce the launch of the ZO Medical product line to the Middle East region at The Dubai World Dermatology & Laser Conference & Exhibition – Dubai Derma, April 8-10, 2014.

31 Mar 2014

Venaxis files 510(k) premarket submission with FDA for APPY1 Test

Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration.

31 Mar 2014

First Edition: March 31, 2014

Today's early morning highlights from the major news organizations offer assessments of the administration's campaign to get people signed up for health care and a look at the issues going forward after today's deadline for most enrollments.

31 Mar 2014

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol.

31 Mar 2014

Medical News

Bariatric surgery patients report better quality of life

NxStage Medical receives American Red Cross Northeast Chapter's Workplace Hero Award

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Verde Media Group, Biotech Division complete acquisition of Butazyme

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

BCBSA honors Empire BlueCross BlueShield with Brand Excellence Award

FitLife Brands' fourth quarter 2013 revenue increases 9% to $3.7 million

Enrollment commences for Daiichi Sankyo's ENSURE-AF multinational phase 3 study in NVAF patients

New study shows anti-anxiety drugs and sleeping pills associated with increased risk of death

ICON agrees to acquire Aptiv Solutions for $143.5 million

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

ZO Skin Health, Cellogique announce launch of ZO Medical products in Middle East

Venaxis files 510(k) premarket submission with FDA for APPY1 Test

First Edition: March 31, 2014

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Genetic markers could help predict heart attack in patients with heart disease

New FDA Roadmap App helps sponsors improve clinical research

e-Therapeutics announces interim results from ETS2101 phase Ia trial for advanced solid tumours

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Directed enzyme evolution and the Nobel Prize: Making enzymes evolve in the lab

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Latest News